DePuy在2010年宣布全球自愿召回93,000个ASR髋关节植入系统，称其中有12％在五年内失败。强生表示至少需要支付24.7亿美元，以解决数千起必须拆除ASR植入物的患者的诉讼。
Johnson & Johnson and its DePuy Orthopaedics unit have agreed to pay $120 million to resolve deceptive marketing claims by several U.S. states over the company's metal-on-metal hip implants.
强生公司及其 DePuy 骨科部门同意支付1.2亿美元，以解决美国几个州对该公司金属对金属髋关节假体的欺骗性营销主张。
Attorneys general of 46 U.S. states announced the settlement agreement in statements on Tuesday. They alleged DePuy engaged in unfair and deceptive practices in the promotion of its ASR XL and Pinnacle Ultamet hip implant devices.
美国46个州的司法部长星期二在声明中宣布了和解协议。他们指控 DePuy 在推广 ASR XL 和 Pinnacle Ultamet 髋部植入器械方面从事不公平和欺骗性的行为。
DePuy in a statement said the settlement involves no admission of liability or misconduct on the part of the companies."DePuy Synthes remains committed to meeting the current and future needs of orthopedic surgeons and patients," the company said.
DePuy 在一份声明中表示，和解不涉及公司承认责任或不当行为。“ DePuy 合成公司仍然致力于满足目前和未来骨科医生和患者的需求，”该公司说。
The states claimed J&J made misleading claims about the longevity of its metal-on-metal hip implants, with patients frequently having to undergo a revision surgery before the company's advertised timeframe of five years.
美国政府称，强生公司对其金属对金属髋关节植入物的使用寿命提出了误导性的说法，患者常常不得不在公司公布的5年期限之前接受一次修正手术。
Under Tuesday's settlement agreement, DePuy is required to maintain a post-market surveillance program and update procedures to track complaints over the hip implants, according to a statement by New York Attorney General Letitia James.
根据周二达成的和解协议， DePuy 必须维持一项上市后的监控计划，并更新程序，以跟踪有关植入髋关节的投诉，根据纽约州总检察长 LetitiaJames 的声明。
DePuy in 2010 announced a worldwide voluntary recall of 93,000 of its ASR hip implant systems, saying that 12 percent of them failed within five years. Saying it would pay at least $2.47 billion, the company has since settled thousands of lawsuits by patients who had to have the ASR implant removed.
DePuy 在2010年宣布在全球范围内自愿召回9.3万个 ASR 髋关节植入系统，称其中12%在五年内失败。该公司称将支付至少24.7亿美元，此后已经解决了数千名患者的诉讼，这些患者必须移除 ASR 植入物。
本文未完，阅读全文请访问www.investank.com
